The UK is one of the heaviest nations in Europe now with 64 per cent of the population overweight or obese, and one in four ...

Mounjaro - the brand name for tirzepatide - has become one of the most talked-about medications in metabolic health, and for good reason. But the conversation around it has gotten tangled up with ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.

Both orforglipron doses showed superiority to both semaglutide doses for mean change at week 52 from baseline HbA1c. HealthDay News — For adults with type 2 diabetes inadequately controlled with ...

Agreement enables Hims & Hers users to access branded Ozempic 0.5–2 mg and Wegovy injectable 0.25–2.4 mg plus oral strengths 1.5–25 mg. Hims & Hers will cease marketing compounded GLP-1 products and ...

With more than 15 years of experience crafting content about all aspects of personal finance, Michael Benninger knows how to identify smart moves for your money. His work has been published by Intuit, ...